Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab
NCT07091695
·
clinicaltrials.gov ↗
COMPLETED
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
Melanoma
Interventions
BIOLOGICAL:
Nivolumab + relatlimab
BIOLOGICAL:
Nivolumab + ipilimumab
Sponsor
Bristol-Myers Squibb